View Future GrowthVirbac 過去の業績過去 基準チェック /46Virbacは、平均年間1.3%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.4% 8.7%収益成長率で 成長しています。 Virbacの自己資本利益率は13.4%であり、純利益率は10.3%です。主要情報1.31%収益成長率1.52%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率8.70%株主資本利益率13.37%ネット・マージン10.30%次回の業績アップデート17 Sep 2026最近の業績更新お知らせ • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026お知らせ • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026お知らせ • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024お知らせ • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023お知らせ • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023すべての更新を表示Recent updatesお知らせ • May 26Virbac SA, Annual General Meeting, Jun 29, 2026Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros Franceお知らせ • Mar 18Virbac Sa Proposes Dividend for the Fiscal Year 2025Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year.お知らせ • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.お知らせ • Dec 17Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million.Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac. Thyronorm has in-market sales of approximately €27 million. Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025.お知らせ • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026お知らせ • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).お知らせ • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.お知らせ • Jun 21Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance.お知らせ • May 13Virbac SA, Annual General Meeting, Jun 19, 2025Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros Franceお知らせ • Mar 14+ 1 more updateVirbac SA Recommends Dividend Distribution for the 2024Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2024 fiscal year.お知らせ • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.お知らせ • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026お知らせ • Dec 04Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S.Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024. Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024.お知らせ • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.お知らせ • Jul 08Virbac Sa Announces Chief Executive Officer ChangesVirbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020.お知らせ • Apr 03Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024.お知らせ • Mar 08Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.お知らせ • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.お知らせ • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024お知らせ • Sep 29Virbac SA Confirms Revenue Forecasts for the Year 2023Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%.お知らせ • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023お知らせ • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023収支内訳Virbac の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:VRBC.F 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 251,465151680030 Sep 251,449142678030 Jun 251,433133675031 Mar 251,415139660031 Dec 241,397145645030 Sep 241,368143625030 Jun 241,339141605031 Mar 241,293131589031 Dec 231,247121573030 Sep 231,229120570030 Jun 231,210119568031 Mar 231,213121563031 Dec 221,216122557030 Sep 221,184120535030 Jun 221,151119513031 Mar 221,107116500031 Dec 211,064113487030 Sep 211,025137473030 Jun 21985161459031 Mar 21960148449031 Dec 20934136439030 Sep 20944104444030 Jun 2095372448031 Mar 2094662451031 Dec 1993852454030 Sep 1992143449030 Jun 1990334445031 Mar 1988627446031 Dec 1886920446030 Sep 188628442030 Jun 18854-4438031 Mar 18858-3440031 Dec 17862-3442030 Sep 1787116444030 Jun 1787935446031 Mar 1787635449031 Dec 1687235452030 Sep 1686130459030 Jun 1685026466031 Mar 1685118463031 Dec 158539460030 Sep 1584621441030 Jun 15839324210質の高い収益: VRBC.Fは 高品質の収益 を持っています。利益率の向上: VRBC.Fの現在の純利益率 (10.3%)は、昨年(10.4%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VRBC.Fの収益は過去 5 年間で年間1.3%増加しました。成長の加速: VRBC.Fの過去 1 年間の収益成長率 ( 3.9% ) は、5 年間の平均 ( 年間1.3%を上回っています。収益対業界: VRBC.Fの過去 1 年間の収益成長率 ( 3.9% ) はPharmaceuticals業界-4.8%を上回りました。株主資本利益率高いROE: VRBC.Fの 自己資本利益率 ( 13.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 19:17終値2026/05/12 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Virbac SA 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Delphine Le LouetBernsteinLaurent GelebartBNP ParibasArnaud CadartCIC Market Solutions (ESN)9 その他のアナリストを表示
お知らせ • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026
お知らせ • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026
お知らせ • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024
お知らせ • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023
お知らせ • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023
お知らせ • May 26Virbac SA, Annual General Meeting, Jun 29, 2026Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros France
お知らせ • Mar 18Virbac Sa Proposes Dividend for the Fiscal Year 2025Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year.
お知らせ • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.
お知らせ • Dec 17Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million.Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac. Thyronorm has in-market sales of approximately €27 million. Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025.
お知らせ • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026
お知らせ • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).
お知らせ • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.
お知らせ • Jun 21Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance.
お知らせ • May 13Virbac SA, Annual General Meeting, Jun 19, 2025Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros France
お知らせ • Mar 14+ 1 more updateVirbac SA Recommends Dividend Distribution for the 2024Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2024 fiscal year.
お知らせ • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.
お知らせ • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026
お知らせ • Dec 04Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S.Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024. Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024.
お知らせ • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.
お知らせ • Jul 08Virbac Sa Announces Chief Executive Officer ChangesVirbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020.
お知らせ • Apr 03Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024.
お知らせ • Mar 08Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.
お知らせ • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.
お知らせ • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024
お知らせ • Sep 29Virbac SA Confirms Revenue Forecasts for the Year 2023Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%.
お知らせ • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023
お知らせ • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023